Pacira Pharmaceuticals Company Profile (NASDAQ:PCRX)

About Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals logoPacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA). DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:PCRX
  • CUSIP: 69512710
  • Web:
  • Market Cap: $1.81 billion
  • Outstanding Shares: 40,093,000
Average Prices:
  • 50 Day Moving Avg: $47.33
  • 200 Day Moving Avg: $41.61
  • 52 Week Range: $29.95 - $58.95
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $280.18 million
  • Price / Sales: 6.46
  • Book Value: $6.76 per share
  • Price / Book: 6.68
  • EBIDTA: ($31,100,000.00)
  • Average Volume: 923,792 shs.
  • Short Ratio: 3.93

Frequently Asked Questions for Pacira Pharmaceuticals (NASDAQ:PCRX)

What is Pacira Pharmaceuticals' stock symbol?

Pacira Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCRX."

How were Pacira Pharmaceuticals' earnings last quarter?

Pacira Pharmaceuticals Inc (NASDAQ:PCRX) released its quarterly earnings results on Thursday, May, 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.04. The firm had revenue of $69.30 million for the quarter, compared to analyst estimates of $70.30 million. The firm's revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.15 EPS. View Pacira Pharmaceuticals' Earnings History.

Where is Pacira Pharmaceuticals' stock going? Where will Pacira Pharmaceuticals' stock price be in 2017?

14 analysts have issued twelve-month price targets for Pacira Pharmaceuticals' stock. Their forecasts range from $36.00 to $87.00. On average, they anticipate Pacira Pharmaceuticals' stock price to reach $56.00 in the next twelve months. View Analyst Ratings for Pacira Pharmaceuticals.

What are analysts saying about Pacira Pharmaceuticals stock?

Here are some recent quotes from research analysts about Pacira Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "The company’s efforts to expand Exparel's label to boost sales in oral surgery and chronic pain are encouraging. The company reported positive topline results for Exparel from its phase IV study in total knee arthroplasty (TKA). The company also collaborated with DePuy Synthes which is expected to significantly expand use of Exparel across a broad range of surgical procedures. Pacira is looking to expand Exparel's label in the animal health market as well. Its share price has underperformed the broader industry in the past one year. However, Pacira’s sole dependence on Exparel for top-line growth is concerning. We are also concerned about the lack of other late-stage candidates in the company’s pipeline. Estimate movement has been mixed lately ahead of the Q1 earnings results. Pacira has a positive record of earnings surprises in recent quarters." (5/2/2017)
  • 2. Mizuho analysts commented, "We continue to like PCRX for the 2017 potential catalyst flow (ahead of the nerve block data), growth opportunities from increased DePuy Synthes (DPS) orthopedic promotion, and a reasonable takeout thesis. We updated our share count and interest expense following the recent convertible debt refinancing, and included the latest Feb data from Symphony. While we are comfortable with the growth rates we estimate for the 20 mL vial, we need to monitor our expectations for the smaller 10 mL vial that launched this year and is not yet reported by Symphony. Our estimates came down slightly due to lowered expectations on this 10 mL vial and we lower our PT to $54 from $59 due to additional share count dilution and increase in net debt." (3/23/2017)

Who are some of Pacira Pharmaceuticals' key competitors?

Who owns Pacira Pharmaceuticals stock?

Pacira Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.48%), Vanguard Group Inc. (7.62%), PARTNER FUND MANAGEMENT, L.P. (5.90%), Westfield Capital Management Co. LP (4.29%), Gilder Gagnon Howe & Co. LLC (3.26%) and State Street Corp (2.76%). Company insiders that own Pacira Pharmaceuticals stock include David M Stack, James B Jones, James S Scibetta, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Paul J Hastings and Scott Braunstein. View Institutional Ownership Trends for Pacira Pharmaceuticals.

Who sold Pacira Pharmaceuticals stock? Who is selling Pacira Pharmaceuticals stock?

Pacira Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Granahan Investment Management Inc. MA, Bank of Nova Scotia, Credit Suisse AG, JPMorgan Chase & Co., Bank of Montreal Can, Morgan Stanley and Suffolk Capital Management LLC. Company insiders that have sold Pacira Pharmaceuticals stock in the last year include David M Stack, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker and Mark A Kronenfeld. View Insider Buying and Selling for Pacira Pharmaceuticals.

Who bought Pacira Pharmaceuticals stock? Who is buying Pacira Pharmaceuticals stock?

Pacira Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Tudor Investment Corp ET AL, Ameriprise Financial Inc., Schroder Investment Management Group, Epoch Investment Partners Inc., Teachers Advisors LLC, Stephens Investment Management Group LLC and Vanguard Group Inc.. Company insiders that have bought Pacira Pharmaceuticals stock in the last two years include James B Jones, James S Scibetta, John P Phd Longenecker and Scott Braunstein. View Insider Buying and Selling for Pacira Pharmaceuticals.

How do I buy Pacira Pharmaceuticals stock?

Shares of Pacira Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Pacira Pharmaceuticals stock cost?

One share of Pacira Pharmaceuticals stock can currently be purchased for approximately $45.15.

Analyst Ratings

Consensus Ratings for Pacira Pharmaceuticals (NASDAQ:PCRX) (?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $56.00 (24.03% upside)

Analysts' Ratings History for Pacira Pharmaceuticals (NASDAQ:PCRX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/24/2017WedbushReiterated RatingOutperform$87.00LowView Rating Details
5/22/2017Canaccord GenuitySet Price TargetBuy$60.00MediumView Rating Details
5/15/2017Royal Bank of CanadaSet Price TargetBuy$58.00LowView Rating Details
5/6/2017HC WainwrightSet Price TargetBuy$59.00LowView Rating Details
5/5/2017MizuhoLower Price TargetBuy -> Buy$57.00 -> $54.00MediumView Rating Details
4/4/2017Jefferies Group LLCSet Price TargetBuy$60.00MediumView Rating Details
3/21/2017Barclays PLCReiterated RatingOverweight -> Overweight$54.00 -> $59.00HighView Rating Details
3/20/2017Leerink SwannReiterated RatingMarket PerformHighView Rating Details
3/14/2017Piper Jaffray CompaniesReiterated RatingOverweight$60.00MediumView Rating Details
3/2/2017Cowen and CompanyReiterated RatingHoldN/AView Rating Details
3/2/2017Janney Montgomery ScottDowngradeNeutral -> Sell$38.00N/AView Rating Details
3/2/2017BMO Capital MarketsReiterated RatingHold$45.00N/AView Rating Details
12/1/2016Goldman Sachs Group IncInitiated CoverageBuy -> Neutral$36.00N/AView Rating Details
10/7/2016Brean CapitalInitiated CoverageHoldN/AView Rating Details
2/28/2016NomuraReiterated RatingBuy$100.00N/AView Rating Details
1/29/2016Bank of America CorpUpgradeNeutral -> Buy$75.00N/AView Rating Details
1/6/2016JMP SecuritiesReiterated RatingMkt Outperform$92.00N/AView Rating Details
(Data available from 5/28/2015 forward)


Earnings History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Earnings by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)
Earnings History by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.23)($0.19)$70.30 million$69.30 millionViewListenView Earnings Details
3/1/2017Q416$0.01$0.09$73.08 million$72.90 millionViewListenView Earnings Details
11/2/2016Q316($0.02)$0.20$67.16 million$68.40 millionViewListenView Earnings Details
8/4/2016Q216$0.03$0.19$67.80 million$69.60 millionViewListenView Earnings Details
5/2/2016Q116$0.07$0.15$67.11 million$65.50 millionViewListenView Earnings Details
2/25/2016Q415$0.27$0.20$68.40 million$69.30 millionViewListenView Earnings Details
10/27/2015Q315$0.15$0.10$60.44 million$62.20 millionViewListenView Earnings Details
7/30/2015Q215$0.04$0.20$62.97 million$59.10 millionViewListenView Earnings Details
4/30/2015Q115$0.02$0.05$61.11 million$58.30 millionViewListenView Earnings Details
2/24/2015Q4$0.27$0.35$61.62 million$61.80 millionViewListenView Earnings Details
10/30/2014Q314$0.10$0.14$52.20 million$52.00 millionViewListenView Earnings Details
7/31/2014Q214($0.21)$0.04$42.20 million$47.20 millionViewListenView Earnings Details
5/1/2014Q1($0.32)($0.19)$35.40 million$36.70 millionViewListenView Earnings Details
2/25/2014Q4($0.31)($0.33)ViewListenView Earnings Details
10/31/2013Q313($0.35)($0.30)$22.10 million$23.30 millionViewListenView Earnings Details
11/1/2012Q312($0.44)($0.49)$7.85 million$8.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.25)($0.25)($0.25)
(Data provided by Zacks Investment Research)


Dividend History for Pacira Pharmaceuticals (NASDAQ:PCRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Insider Trades by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)
Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)
Insider Trades by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017James S ScibettaPresidentSell20,000$51.20$1,024,000.00View SEC Filing  
5/15/2017Kristen Marie WilliamsCAOSell21,041$50.86$1,070,145.26View SEC Filing  
1/17/2017David M. StackCEOSell15,000$38.41$576,150.00View SEC Filing  
1/17/2017James S ScibettaPresidentSell20,000$38.53$770,600.00View SEC Filing  
8/15/2016David M. StackCEOSell15,000$45.32$679,800.00View SEC Filing  
8/15/2016James S. ScibettaPresidentSell25,000$45.21$1,130,250.00View SEC Filing  
6/7/2016Lauren Bullaro RikerVPSell938$47.66$44,705.08View SEC Filing  
6/6/2016Kristen Marie WilliamsCAOSell600$47.20$28,320.00View SEC Filing  
6/6/2016Lauren Bullaro RikerVPSell321$47.20$15,151.20View SEC Filing  
6/6/2016Mark A KronenfeldDirectorSell900$46.95$42,255.00View SEC Filing  
4/15/2016David M StackCEOSell25,000$64.14$1,603,500.00View SEC Filing  
1/29/2016Scott BraunsteinSVPBuy2,000$58.92$117,840.00View SEC Filing  
1/27/2016James B JonesSVPBuy500$62.50$31,250.00View SEC Filing  
1/15/2016David M. StackCEOSell15,000$63.84$957,600.00View SEC Filing  
1/12/2016James B JonesSVPBuy1,000$66.00$66,000.00View SEC Filing  
1/12/2016John P Phd LongeneckerDirectorBuy300$66.55$19,965.00View SEC Filing  
10/15/2015David M. StackCEOSell15,000$37.57$563,550.00View SEC Filing  
9/11/2015James S ScibettaCFOBuy5,000$61.37$306,850.00View SEC Filing  
8/17/2015Paul J HastingsDirectorSell3,000$60.02$180,060.00View SEC Filing  
7/15/2015David M StackCEOSell15,000$67.78$1,016,700.00View SEC Filing  
4/15/2015David M StackCEOSell25,000$90.50$2,262,500.00View SEC Filing  
4/10/2015Paul J HastingsDirectorSell2,500$88.00$220,000.00View SEC Filing  
3/16/2015Lauren Bullaro RikerDirectorSell5,000$95.34$476,700.00View SEC Filing  
3/13/2015Gary W PaceDirectorBuy1,000$93.83$93,830.00View SEC Filing  
2/6/2015James S ScibettaCFOSell15,000$111.22$1,668,300.00View SEC Filing  
1/15/2015David M StackCEOSell15,000$97.52$1,462,800.00View SEC Filing  
1/12/2015Paul J HastingsDirectorSell2,500$94.06$235,150.00View SEC Filing  
12/29/2014John P Phd LongeneckerDirectorSell1,000$93.32$93,320.00View SEC Filing  
12/5/2014Dennis L WingerDirectorBuy2,645$94.54$250,058.30View SEC Filing  
11/7/2014James S ScibettaCFOSell15,000$87.18$1,307,700.00View SEC Filing  
11/7/2014Taunia MarkvickaSVPBuy230$86.62$19,922.60View SEC Filing  
10/10/2014Paul J HastingsDirectorSell2,500$94.87$237,175.00View SEC Filing  
9/29/2014John P Phd LongeneckerDirectorSell1,000$96.40$96,400.00View SEC Filing  
8/29/2014Andreas WickiDirectorSell21,494$108.11$2,323,716.34View SEC Filing  
8/27/2014Andreas WickiDirectorSell55,813$108.08$6,032,269.04View SEC Filing  
8/26/2014Andreas WickiDirectorSell24,207$108.11$2,617,018.77View SEC Filing  
8/25/2014Andreas WickiDirectorSell30,000$108.07$3,242,100.00View SEC Filing  
8/11/2014Andreas WickiDirectorSell150,000$101.25$15,187,500.00View SEC Filing  
8/8/2014James S ScibettaCFOSell15,000$99.63$1,494,450.00View SEC Filing  
8/7/2014Gary PatouInsiderSell20,000$100.26$2,005,200.00View SEC Filing  
7/15/2014David M StackCEOSell15,000$86.75$1,301,250.00View SEC Filing  
7/14/2014Gary PatouInsiderSell29,700$86.96$2,582,712.00View SEC Filing  
7/10/2014Paul J HastingsDirectorSell2,500$84.41$211,025.00View SEC Filing  
6/6/2014Andreas WickiDirectorSell67,900$82.62$5,609,898.00View SEC Filing  
6/3/2014Andreas WickiDirectorSell68,000$80.69$5,486,920.00View SEC Filing  
5/27/2014Andreas WickiDirectorSell64,400$77.93$5,018,692.00View SEC Filing  
5/21/2014Andreas WickiDirectorSell3,600$77.80$280,080.00View SEC Filing  
5/12/2014Gary PatouInsiderSell30,000$74.39$2,231,700.00View SEC Filing  
5/9/2014David StackCEOSell25,000$73.94$1,848,500.00View SEC Filing  
5/9/2014Laura BregeDirectorSell10,000$73.85$738,500.00View SEC Filing  
5/8/2014Andreas WickiDirectorSell23,220$75.76$1,759,147.20View SEC Filing  
5/8/2014James ScibettaCFOSell15,000$75.05$1,125,750.00View SEC Filing  
5/7/2014Andreas WickiDirectorSell44,780$75.78$3,393,428.40View SEC Filing  
3/28/2014John Phd LongeneckerDirectorSell1,000$64.63$64,630.00View SEC Filing  
3/6/2014Andreas WickiDirectorSell24,887$80.16$1,994,941.92View SEC Filing  
12/30/2013David StackCEOSell15,000$55.84$837,600.00View SEC Filing  
12/30/2013James ScibettaCFOSell10,000$55.55$555,500.00View SEC Filing  
12/30/2013John Phd LongeneckerDirectorSell2,500$55.55$138,875.00View SEC Filing  
10/1/2013Gary PatouInsiderSell20,000$48.92$978,400.00View SEC Filing  
9/11/2013Andreas WickiDirectorSell17,783$37.25$662,416.75View SEC Filing  
8/14/2013Taunia MarkvickaVPSell14,700$37.00$543,900.00View SEC Filing  
7/22/2013Andreas WickiDirectorSell75,958$35.06$2,663,087.48View SEC Filing  
7/18/2013Andreas WickiDirectorSell25,560$33.45$854,982.00View SEC Filing  
7/16/2013Andreas WickiDirectorSell48,482$33.28$1,613,480.96View SEC Filing  
7/12/2013Taunia MarkvickaVPSell29,754$32.00$952,128.00View SEC Filing  
7/11/2013Andreas WickiDirectorSell80,000$31.48$2,518,400.00View SEC Filing  
7/5/2013Andreas WickiDirectorSell44,021$30.80$1,355,846.80View SEC Filing  
7/3/2013Andreas WickiDirectorSell114,448$30.21$3,457,474.08View SEC Filing  
7/2/2013Gary PatouInsiderSell40,000$29.44$1,177,600.00View SEC Filing  
6/28/2013David M StackCEOSell15,000$28.73$430,950.00View SEC Filing  
6/28/2013James S ScibettaCFOSell10,000$28.05$280,500.00View SEC Filing  
6/28/2013John P Phd LongeneckerDirectorSell2,000$28.09$56,180.00View SEC Filing  
6/24/2013Fred A MiddletonDirectorSell75,900$29.13$2,210,967.00View SEC Filing  
6/20/2013Fred A MiddletonDirectorSell144,100$29.32$4,225,012.00View SEC Filing  
6/19/2013Andreas WickiDirectorSell35,407$29.90$1,058,669.30View SEC Filing  
6/17/2013Andreas WickiDirectorSell50,145$29.86$1,497,329.70View SEC Filing  
6/13/2013John PrattInsiderSell21,032$30.00$630,960.00View SEC Filing  
6/13/2013Luke EvninDirectorSell22,746$30.07$683,972.22View SEC Filing  
6/12/2013Andreas WickiDirectorSell4,409$30.00$132,270.00View SEC Filing  
6/11/2013Andreas WickiDirectorSell11,500$30.00$345,000.00View SEC Filing  
6/11/2013John PrattInsiderSell18,343$30.00$550,290.00View SEC Filing  
6/5/2013Andreas WickiDirectorSell15,500$30.26$469,030.00View SEC Filing  
6/3/2013Andreas WickiDirectorSell1,900$30.00$57,000.00View SEC Filing  
5/31/2013Luke EvninDirectorSell54,517$30.00$1,635,510.00View SEC Filing  
5/29/2013Luke EvninDirectorSell215,528$30.86$6,651,194.08View SEC Filing  
5/22/2013Andreas WickiDirectorSell18,471$30.00$554,130.00View SEC Filing  
5/20/2013Andreas WickiDirectorSell14,374$30.00$431,220.00View SEC Filing  
3/25/2013Andreas WickiDirectorSell290,900$27.95$8,130,655.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Pacira Pharmaceuticals (NASDAQ:PCRX)
Latest Headlines for Pacira Pharmaceuticals (NASDAQ:PCRX)
DateHeadline logoOpioids are still the best pain drug we’ve got - May 26 at 8:24 PM logoPacira Pharmaceuticals Announces Resignation of James Scibetta - GlobeNewswire (press release) - May 25 at 5:28 AM logoWedbush Reaffirms Outperform Rating for Pacira Pharmaceuticals Inc (PCRX) - May 24 at 11:32 AM logoPacira Pharmaceuticals Inc (PCRX) Given a $60.00 Price Target at Canaccord Genuity - May 23 at 9:58 PM logoPacira Pharma (PCRX) President, James Scibetta Confirms Resignation - May 23 at 6:37 PM logoPacira Pharmaceuticals Announces Resignation of James Scibetta - May 23 at 6:37 PM logoETFs with exposure to Pacira Pharmaceuticals, Inc. : May 22, 2017 - May 22 at 6:19 PM logoPacira Pharmaceuticals, Inc. :PCRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 - May 19 at 11:55 AM logoPacira Pharmaceuticals Inc (PCRX) President Sells $1,024,000.00 in Stock - May 17 at 10:29 PM logoPacira Pharmaceuticals Inc (PCRX) CAO Kristen Marie Williams Sells 21,041 Shares - May 17 at 10:29 PM logoZacks: Analysts Expect Pacira Pharmaceuticals Inc (PCRX) to Announce -$0.27 Earnings Per Share - May 17 at 10:28 AM logoPacira Pharmaceuticals Inc (PCRX) Given a $58.00 Price Target by Royal Bank of Canada Analysts - May 15 at 3:14 PM logoPacira Pharmaceuticals Inc (PCRX) Receives Consensus Rating of "Hold" from Analysts - May 12 at 11:45 AM logoPacira Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference - May 10 at 11:45 AM logoPacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PCRX-US : May 8, 2017 - May 8 at 12:06 PM logoMizuho Trims Pacira Pharmaceuticals Inc (PCRX) Target Price to $54.00 - May 6 at 3:22 PM logoPacira Pharmaceuticals' (PCRX) "Buy" Rating Reaffirmed at Canaccord Genuity - May 5 at 9:34 PM logoEdited Transcript of PCRX earnings conference call or presentation 4-May-17 12:30pm GMT - May 5 at 8:45 AM logoPacira Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results - Yahoo Finance - May 5 at 12:23 AM logoPacira Pharmaceuticals (PCRX) Q1 2017 Results - Earnings Call Transcript - May 4 at 7:21 PM logoPacira Pharmaceuticals Inc (PCRX) Announces Earnings Results, Misses Expectations By $0.17 EPS - May 4 at 5:24 PM logoPacira reports 1Q loss - May 4 at 8:45 AM logoPacira Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results - GlobeNewswire (press release) - May 4 at 8:06 AM logoInvestor Network: Pacira Pharmaceuticals, Inc. to Host Earnings Call - May 4 at 8:06 AM logoPacira Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results - May 4 at 8:06 AM logoNew Research Shows Vast Majority of Oral Surgery Patients Would Choose Non-opioid Medication to Treat Postsurgical Pain if Given the Option - May 3 at 7:54 PM logoPacira Pharmaceuticals (PCRX) Earning Favorable Media Coverage, Analysis Finds - May 3 at 5:46 PM logoPacira Pharmaceuticals Inc (PCRX) Lowered to "Sell" at Zacks Investment Research - May 2 at 2:28 PM logo$70.46 Million in Sales Expected for Pacira Pharmaceuticals Inc (PCRX) This Quarter - April 28 at 3:11 PM logoSomewhat Critical Media Coverage Extremely Likely to Affect Pacira Pharmaceuticals (PCRX) Share Price - April 27 at 4:24 PM logoPacira Pharmaceuticals Announces Timing for First Quarter 2017 Financial Results Webcast and Conference Call - April 27 at 10:22 AM logoPacira Pharmaceuticals Inc (PCRX) Expected to Announce Earnings of -$0.24 Per Share - April 26 at 6:54 PM logoPacira Pharmaceuticals' (PCRX) "Outperform" Rating Reaffirmed at Wedbush - April 25 at 11:37 AM logoPacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PCRX-US : April 25, 2017 - April 25 at 9:37 AM logoSomewhat Favorable News Coverage Extremely Likely to Affect Pacira Pharmaceuticals (PCRX) Share Price - April 24 at 7:01 PM logoPacira Pharmaceuticals Inc (PCRX) Sees Large Drop in Short Interest - April 21 at 10:59 AM logoPacira Pharmaceuticals Inc (PCRX) Expected to Earn Q1 2017 Earnings of ($0.25) Per Share - April 21 at 7:35 AM logoCan Pacira Pharmaceuticals' Exparel Reduce Opioid Abuse? - April 19 at 9:58 AM logoCan Drugmakers Cure the Opioid Crisis? - April 18 at 9:51 AM logoPacira Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PCRX) : April 17, 2017 - April 17 at 6:18 PM logoSomewhat Positive Press Coverage Extremely Likely to Effect Pacira Pharmaceuticals (PCRX) Stock Price - April 17 at 1:44 PM logoPacira Pharmaceuticals Inc (PCRX) Given Consensus Rating of "Hold" by Brokerages - April 17 at 12:46 PM logoPacira Pharmaceuticals (PCRX) Getting Somewhat Positive Press Coverage, Analysis Shows - April 13 at 3:54 PM logoPacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PCRX-US : April 13, 2017 - April 13 at 9:53 AM logoPacira Pharmaceuticals Inc (PCRX) Receives New Coverage from Analysts at Royal Bank of Canada - April 13 at 9:16 AM logoPacira Focuses on Lead Candidate Exparel's Label Expansion - April 12 at 1:15 PM logoPacira Focuses on Lead Candidate Exparel's Label Expansion - April 12 at 1:15 PM logoMonoSol Rx Appoints James S. Scibetta to Board of Directors - April 11 at 10:35 AM logoPacira Pharmaceuticals (PCRX) Presents At 16th Annual Needham Healthcare Conference - Slideshow - April 7 at 11:50 AM logoBrokerages Anticipate Pacira Pharmaceuticals Inc (PCRX) to Post ($0.23) Earnings Per Share - April 6 at 8:07 AM



Pacira Pharmaceuticals (PCRX) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by Staff